Actively Recruiting
Study on Clinical Features, Treatment, and Outcomes in Children with Primary Immune Thrombocytopenia in China
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-02-11
500
Participants Needed
1
Research Sites
521 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to study pediatric primary immune thrombocytopenia ITP, a rare autoimmune disease in children characterized by low platelet counts and bleeding issues. The study focuses on analyzing clinical features, treatment methods, prognosis, and developing prognostic models in children with ITP within China. It addresses the lack of large-scale, comprehensive prospective data on pediatric ITP in this population. Participants diagnosed with primary ITP between ages 6 and 17 will be enrolled from multiple hospitals. The study collects detailed information from medical records about diagnosis and treatments, and uses questionnaires to evaluate patient exposures. Researchers will prospectively follow patients over time to gather data on disease progression and outcomes. During the study, patients will be regularly assessed for treatment responses, bleeding events, and survival without recurrence over three years. Various outcome measures include overall response rate, duration of response, emergency treatments, and bleeding severity using pediatric and WHO scales. The study also explores prognostic factors through advanced analyses of transcriptome, proteomics, metabolomics, and microbiome data. Safety and adverse events related to treatments will be monitored throughout the follow-up period.
CONDITIONS
Brief Title
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Research Team
T
Ting Sun, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here